Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands

Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands

Viemed sees a sizable untapped home-ventilation market: Only about 60,000 beneficiaries currently receive its ventilation therapy, versus an estimated 1.25 million Medicare-eligible potential patients. The company serves more than 198,000 patients nationwide and focuses on complex respiratory conditions such as severe COPD. Management expects low-20% revenue growth in 2026, projecting approximately $317 million in revenue and $66 million in EBITDA. Growth is supported by expanding sleep-resupply and maternal-health businesses, although these lower-margin segments may pressure EBITDA margins. Viemed is prioritizing organic growth, strategic acquisitions and share repurchases while maintaining a debt-free balance sheet. The company has completed three acquisitions in three years and says leverage would remain below roughly two times EBITDA for any major deal.

Viemed Healthcare NASDAQ: VMD outlined its growth strategy, product diversification and capital allocation priorities at the Midwest IDEAS Conference, emphasizing its focus on providing in-home care for patients with complex respiratory conditions. Chief Executive Officer Casey Hoyt said complex respiratory services account for roughly half of the company’s business. Viemed deploys respiratory therapists to care for patients at home, including those with chronic obstructive pulmonary disease, ALS and neuromuscular conditions that can cause respiratory failure. The company also provides sleep apnea products, oxygen therapy, airway-clearance devices, healthcare staffing and maternal health products. Get Viemed Healthcare alerts: Sign Up Hoyt said Viemed serves patients in all 50 states and has more than 198,000 patients. He characterized the company’s primary opportunity as the underpenetrated market for home ventilation among patients with severe COPD. Of an estimated 25 million Americans with COPD, he said about 10% are in the most severe stage of the disease and roughly half of those may have chronic respiratory failure, making them potential candidates for ventilation therapy. Home respiratory opportunity and technology According to Hoyt, approximately 60,000 beneficiaries currently receive the company’s type of ventilation therapy, compared with an estimated 1.25 million Medicare-eligible patients who could qualify. He said Medicare penetration is about 5%, with overall penetration potentially near 10% after accounting for commercial payers. For its ventilator business, Viemed receives about $1,050 per month on average for a machine on rent, Hoyt said. The rentals are uncapped, meaning the company can bill while the patient remains alive, and the average patient length of stay is about 17 months. Once equipment is returned, it can be cleaned, serviced and deployed to another patient. The company has developed technology that connects respiratory equipment with a tablet used by respiratory therapists in patients’ homes. Hoyt said the system supports telehealth visits, captures therapy data, helps identify when a field visit may be needed and provides reporting for physicians and payers. He said the platform has also helped Viemed document patient compliance under a recently implemented National Coverage Determination governing qualification for ventilation therapy. Hoyt cited three peer-reviewed studies funded by Viemed in 2021 and 2022. He said the studies found that the company’s care model reduced relative mortality by 43% and that early therapy utilization could save $5,400 per patient annually by reducing hospital and clinic visits. Diversification and acquisitions While ventilation represented 47% of reven...